Yaneth Rodríguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yaneth Rodríguez has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Ochoa
Department of Neurogenetics and Molecular Biology, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico
1 shared publication - Ana Luisa Sosa
Laboratory of the Dementias, National Institute of Neurology and Neurosurgery, Mexico City, Mexico
1 shared publication - Astrid Rasmussen
Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
1 shared publication - Irene De Biase
Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
1 shared publication - Itziar Familiar
Department of Psychiatry, Michigan State University, East Lansing, USA
1 shared publication - Marisol López-López
Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana Unidad Xochimilco, Mexico City 04960, Mexico
1 shared publication
Latest Publications
- Open Access
- 12 January 2010
- Published by Springer Nature in BMC Medical Genetics
- Vol. 11 (1) , 4
Uptake of genetic testing and long-term tumor surveillance in von Hippel-Lindau disease
Von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome caused by germline mutations in the VHL gene. Patients have significant morbidity and mortality secondary to vascular tumors. Disease management is centered on tumor surveillance that allows early detection and treatment. Presymptomatic genetic testing is therefore recommended, including in at-risk children.
- 12 January 2010
- Published by Springer Nature in BMC Medical Genetics
- Vol. 11 (1) , 4
Open AccessUptake of genetic testing and long-term tumor surveillance in von Hippel-Lindau disease
Von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome caused by germline mutations in the VHL gene. Patients have significant morbidity and mortality secondary to vascular tumors. Disease management is centered on tumor surveillance that allows early detection and treatment. Presymptomatic genetic testing is therefore recommended, including in at-risk children.